Medication info

Linagliptin and Metformin Hydrochloride Tablets 2.5/850 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Dongwha Pharmaceutical Co., Ltd.
Appearance
Biconvex oval film-coated tablet with bright orange color
Packaging
30 tablets/bottle, 60 tablets/bottle
Approval status
Expired

MFDS item code 201904472 · Approved 2019.06.28

This product's status changed to Expired on 2024.06.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improves blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Determine the dose of this medicine based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose for each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this medicine twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience with diabetes drug therapy whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their previous doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Careful Administration). 5. Patients whose blood glucose is not adequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Careful Administration). No studies have been conducted to evaluate the safety and efficacy of switching patients from other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. As the initial dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Patients Who Must Not Receive This Medicine).

Ingredients

Manufacturer
Dongwha Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in type 2 diabetes mellitus

View approved original text

This medication is used for patients with type 2 diabetes who require both linagliptin and metformin. It serves as an adjunct to effectively help manage blood sugar levels in conjunction with dietary and exercise regimens. Therefore, it aids in maintaining stable blood sugar levels, which can lead to positive effects in the treatment of diabetes.

How to take

Adult dose

Determine the dose of this medicine based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose for each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this medicine twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience with diabetes drug therapy whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their previous doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Careful Administration). 5. Patients whose blood glucose is not adequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Careful Administration). No studies have been conducted to evaluate the safety and efficacy of switching patients from other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. As the initial dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Patients Who Must Not Receive This Medicine).

Precautions

This medication helps control blood sugar levels and is used primarily for the treatment of type 2 diabetes. This drug may cause a serious side effect called lactic acidosis in some patients; therefore, it should not be used by individuals with impaired kidney function or certain health conditions. Additionally, individuals who have an allergy to any of the components in this medication, those with type 1 diabetes, acute heart disease, liver dysfunction, heart failure, pregnant women, etc., should avoid its use. There is a risk of hypoglycemia, so one must closely monitor blood sugar levels when used in conjunction with insulin or sulfonylureas. Hypoglycemia may also occur if there is insufficient caloric intake or excessive exercise. Patients with diminished kidney function should undergo regular kidney function tests before using this medication, and should temporary stop using it if acute kidney injury is suspected. Acute pancreatitis or dermatosis with blistering may occur; therefore, if severe abdominal pain or skin abnormalities occur during use, consult a doctor immediately. This medication may lower vitamin B12 levels, so it is advisable to regularly check blood levels of vitamin B12 during long-term use. Furthermore, alcohol consumption can increase the risk of lactic acidosis, so it is safer to avoid alcohol. Pregnant or breastfeeding women are advised not to use this medication. In elderly patients, decreased kidney function is common, so treatment should begin at the lowest doses, with regular assessments of kidney function. This medication may interact with other drugs, so it is essential to inform your doctor or pharmacist if you are taking other medications, especially those that may affect kidney function. If you are receiving iodine-based contrast for surgery or radiographic examination, this medication should be temporarily discontinued, and resumed only after kidney function stabilizes. In case of overdose, gastrointestinal symptoms or lactic acidosis may occur, requiring immediate medical attention.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased vitamin B12 and deficiency
  • hypoglycemia
  • taste disorders
  • cough
  • decreased appetite
Show 133 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • pemphigoid
  • severe and debilitating arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer-type dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage kidney disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hyperglycemia
  • dyspnea
  • nosebleeds
  • oropharyngeal pain
  • voice disorder
  • allergic rhinitis
  • exertional dyspnea
  • wet cough
  • rhinorrhea
  • pulmonary mass
  • arthralgia
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • pruritus
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • dry eyes
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • thyroid goiter
  • anemia
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • gastroenteritis
  • stomatitis
  • increased serum creatinine
  • chest discomfort
  • weakness
  • pain
  • nosebleeds
  • oropharyngeal pain
  • voice disorder
  • dizziness
  • dyslipidemia
  • hypercholesterolemia
  • confusion
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to avoid exposure to air and moisture. It is advisable to maintain a storage temperature between 1 to 30 degrees Celsius. Doing so ensures that the effectiveness of the medication is preserved safely.

Appearance and packaging

Appearance

Biconvex oval film-coated tablet with bright orange color

Package unit

30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.